Our mission is to discover treatments and a cure for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest.
The Hoffman ALS Clinical Trial Awards Program focuses on the development of new and better therapies for ALS by supporting early-stage clinical trials. These trials aim to produce essential data on safety, dosing, and biomarkers that are crucial for moving investigational therapies closer to FDA evaluation. The program emphasizes the importance of these trials in de-risking future drug development stages and attracting necessary follow-on funding. It provides up to $1,000,000 over 2 to 3 years for trials that are in the early to mid-phase of clinical testing (phase 1 or phase 2a), involve individuals living with ALS, healthy subjects, or asymptomatic carriers of ALS-linked genetic mutations, and test novel or repurposed approaches for ALS treatment, including a wide range of therapeutic methods.
non aliquip excepteur ullamco labore aute et elit Lorem anim est enim aliqua tempor id do nostrud eiusmod consectetur nulla magna deserunt id ipsum reprehenderit exercitation dolore laborum est fugiat cupidatat ut deserunt veniam quis et magna ea eiusmod Lorem elit commodo irure velit velit sit ex cupidatat dolore laborum sint esse ex officia cillum aute deserunt qui dolor esse in dolore culpa aute et mollit Lorem